90. 網膜色素変性症 Retinitis pigmentosa Clinical trials / Disease details


臨床試験数 : 130 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02609165
(ClinicalTrials.gov)
May 201512/10/2015Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaNerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II TrialRetinitis Pigmentosa;Cystoid Macular EdemaDrug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye dropsOspedale San RaffaeleDompé Farmaceutici S.p.ACompleted18 YearsN/AAll45Phase 2Italy
2EUCTR2014-000385-22-IT
(EUCTR)
07/10/201412/05/2014Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa.Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical toclinical Phase II trial. - NEMO Retinitis pigmentosa with cystoid macular edema
MedDRA version: 17.0;Level: LLT;Classification code 10054467;Term: Macular edema;System Organ Class: 100000004853
MedDRA version: 17.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: recombinant human Nerve Growth Factor (rhNGF)
INN or Proposed INN: not yet assigned
Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF)
Ospedale San Raffaele di MilanoNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Italy
3NCT02110225
(ClinicalTrials.gov)
January 20148/4/2014A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.Retinitis PigmentosaDrug: rhNGF 60 µg/ml eye drops solution;Drug: rhNGF 180 µg/ml eye drops solution;Drug: PlaceboDompé Farmaceutici S.p.ANULLCompleted18 YearsN/AAll50Phase 1/Phase 2Italy